Cargando…
Nanotechnology and the brain /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Cambridge, MA :
Academic Press is an imprint of Elsevier,
2016.
|
| Colección: | International review of neurobiology ;
v. 130. |
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Nanotechnology and the Brain; Copyright; Contents; Contributors; Preface; Chapter One: Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted The ...; 1. Introduction; 2. Lipid-Based Nanoparticles for Nucleic Acid and Drug Delivery to the CNS; 2.1. Ischemic Stroke; 2.2. Neuropathic Pain; 2.3. Alzheimer�s Disease; 2.4. Parkinson�s Disease; 2.5. Machado-Joseph Disease; 2.6. Multiple Sclerosis; 2.7. CNS Tumors; 2.8. Other Neurological Disorders; 3. Exosomes as Delivery Systems for CNS Diseases; 4. Conclusions; Acknowledgments
- 1. Introduction2. NPs for Brain Cancer; 2.1. Physiopathology; 2.1.1. Brain Tumors and Glioblastoma; 2.1.1.1. Brain Tumors; 2.1.1.2. Glioblastoma; 2.2. Standard Treatments; 2.2.1. Current GB Therapies; 2.2.1.1. Surgery; 2.2.1.2. Chemotherapy; 2.2.1.3. Radiotherapy; 2.2.2. Therapeutic Limitations; 2.3. NP-Based GB Therapy; 2.3.1. Advantages; 2.3.1.1. Suitable Drugs; 2.3.1.2. Pharmacokinetic Modulation; 2.3.1.3. Targeting; 2.3.1.4. Crossing Barrier Facilitation; 2.3.1.5. Theranostic Medicine; 2.3.1.6. Gene Therapy; 2.3.2. Preclinical Phase and Clinical Trials; 2.3.2.1. Preclinical Phase
- 2.3.2.2. Clinical Trials2.3.3. Limits of NP-Based GB Therapies; 2.4. Novel NP-Based Approaches for GB Treatment; 2.5. Conclusion on the Application of Nanomedicine to GB Therapy; 3. NPs for Alzheimer�s Disease Therapy; 3.1. Physiopathology; 3.1.1. Neurodegenerative Diseases and Alzheimer�s Disease; 3.1.1.1. Neurodegenerative Diseases; 3.1.1.2. Alzheimer�s Disease; 3.2. Conventional Treatments; 3.2.1. Current Therapy and Research Strategies; 3.2.1.1. Therapeutics Based on ``Cholinergic Hypothesis��; 3.2.1.2. Therapeutics Based on ``Tau Cascade Hypothesi��s
- 3.2.1.3. Therapeutics Based on ``Amyloid Cascade Hypothesis��3.2.2. Limitations of ADs Therapies; 3.3. NP-Based AD Therapies; 3.3.1. Nanotechnological Improvement and Innovation; 3.3.1.1. Nanotechnological Improvement; 3.3.1.2. Nanotechnological Innovation; 3.3.2. Preclinical Phase and Clinical Trials; 3.4. Conclusions on the Application of Nanomedicine to Alzheimer Disease Therapy; 4. Nanotechnology for the Treatment of Stroke; 4.1. Physiopathology of Stroke; 4.2. Current Stroke Therapies; 4.2.1. Thrombolysis; 4.2.2. Neuroprotective Therapy; 4.3. NP-Based Stroke Therapy; 4.3.1. Advantages